



an Open Access Journal by MDPI

Drug Therapy for Glioma

Guest Editors:

Dr. Kok Siong Chen

Center for Stem Cell and
Translational Immunotherapy,
Department of Neurosurgery,
Brigham and Women's Hospital,
Harvard Medical School, Boston,
MA, USA

Dr. Lucia Moreno-Lama

Center for Stem Cell and
Translational Immunotherapy,
Department of Neurosurgery,
Brigham and Women's Hospital,
Harvard Medical School, Boston,
MA, USA

Dr. Filippo Rossignoli

Center for Stem Cell and
Translational Immunotherapy,
Department of Neurosurgery,
Brigham and Women's Hospital,
Harvard Medical School, Boston,
MA, USA

Message from the Guest Editors

Gliomas are the most common brain tumors originating from glial cells. Among the malignant gliomas, grade IV glioma, or glioblastoma (GBM), is the most aggressive form. Despite advances in surgery, radiotherapy and chemotherapy, the median survival of GBM patients remains at just 12–15 months. Adjuvant chemotherapy is an important treatment component, yet standard systemic routes often demonstrate toxicity and limited crossing through the blood–brain-barrier. Due to the significant inter-tumoral molecular heterogeneity of GBMs, biomarker-driven therapy that targets specific alterations in GBM is increasingly recognized as the optimum method to improve patient outcomes and reduce toxicity. Therefore, more pre-clinical and clinical trials are urgently needed to explore and evaluate the feasibility of targeted therapy with the corresponding biomarkers for effective treatment options.

This Special Issue aims to review the potential novel drug agents, and the current status of preclinical and clinical trials, and explore the challenges and future perspectives in glioma drug therapy.

Deadline for manuscript
submissions:

25 May 2024



mdpi.com/si/166719

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com